Cai Z, Zhang G, Zhou Z, Bembas K, Drebin J A, Greene M I, Zhang H
Department of Pathology/Lab Medicine, University of Pennsylvania School of Medicine, Hamilton Walk, Philadelphia, PA 19104, USA.
Oncogene. 2008 Jun 19;27(27):3870-4. doi: 10.1038/onc.2008.13. Epub 2008 Feb 11.
2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB3. In our studies of epidermal growth factor receptor (EGFR)-p185(her2/neu) heterodimerization, we noted that 2C4 formed associations with the EGFR-p185(her2/neu) receptor complex. Our data argue against 2C4 as a universal heterodimerization blocker for p185(her2/neu), but indicate that cocktails of monoclonal antibodies binding distinct interaction surfaces of p185(her2/neu) will emerge as the most potent targeted therapy.
2C4（帕妥珠单抗，商品名：Omnitarg）是一种靶向p185（her2/neu）的单克隆抗体，在30%的浸润性乳腺癌中该蛋白呈过表达。2C4目前正处于针对多种癌症的II期临床试验阶段。据报道，这种抗体可破坏p185（her2/neu）与ErbB3之间的结合。在我们对表皮生长因子受体（EGFR）-p185（her2/neu）异源二聚化的研究中，我们注意到2C4与EGFR-p185（her2/neu）受体复合物形成了结合。我们的数据表明2C4并非p185（her2/neu）的通用异源二聚化阻断剂，但表明结合p185（her2/neu）不同相互作用表面的单克隆抗体组合将成为最有效的靶向治疗方法。
